Blau Farmacêutica (BLAU3) Q3 2024 earnings summary

Executive summary

• Achieved record net revenue of BRL 474 million in 3Q24, up 31% year-over-year, driven by organic growth in the hospital segment and successful new product launches.

• Gross profit rose 68% year-over-year to BRL 187 million, with gross margin expanding to 39.5%.

• Recurring EBITDA reached BRL 118 million, up 139% year-over-year, with margin at 24.9%.

• Recurring net income was BRL 69 million, 2.7x higher than 3Q23, with net margin at 14.6%.

• Cash conversion cycle improved to 218 days, down 54 days year-over-year, reflecting working capital optimization.

Financial highlights

• Net revenue: BRL 474 million (+31% YoY, +2% QoQ); Hospital segment contributed BRL 413 million (+35% YoY).

• Gross profit: BRL 187 million (+68% YoY, +10% QoQ); gross margin: 39.5% (+880bps YoY, +300bps QoQ).

• Recurring EBITDA: BRL 118 million (+139% YoY, +29% QoQ); margin: 24.9% (+1,130bps YoY, +530bps QoQ).

• Recurring net income: BRL 69 million (+171% YoY, +34% QoQ); margin: 14.6% (+760bps YoY, +340bps QoQ).

• Free cash flow to equity: BRL 77 million in 3Q24.

Outlook and guidance

• Management expects continued margin expansion and revenue growth, supported by investments in production capacity, R&D, and innovation.

• Pipeline of product launches with TAM of BRL 714 million for 2024, aiming for BRL 1.4 billion in 2025 and cumulative TAM of BRL 7.4 billion through 2027.

• Ongoing investments in monoclonal antibodies and expansion of manufacturing lines to support growth through 2027.

• Expectation of further revenue acceleration and margin gains as new products mature and operational efficiencies are realized.

• Plans to maintain low leverage and prioritize cash generation amid high interest rates.